Early-stage oncology startup Boundless Bio files for IPO 03/06/2024
Boundless Bio has filed to go public as it approaches early safety and efficacy data for its first clinical attempt at a unique take on treating cancer. The five-year-old San Diego startup revealed its plans [...]
A step towards clinic-ready patient-derived organoids 03/06/2024
LA JOLLA—Pancreatic cancer has the highest mortality rate of all major cancers and is projected to become the second-leading cause of cancer-related deaths in the United States by 2030. It is especially difficult to treat [...]
This Injectable Hydrogel Mitigates Damage to the Right Ventricle of the Heart 03/06/2024
An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study published March 6 in Journals of the American College of Cardiology: Basic to [...]
MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results. 03/06/2024
SAN DIEGO–(BUSINESS WIRE)–MediPrint® Ophthalmics, a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study. The Phase IIb trial was an active-controlled, randomized, [...]
Healable Cathode Could Unlock Potential of Solid-state Lithium-sulfur Batteries 03/06/2024
UC San Diego engineers developed a cathode material for lithium-sulfur (Li-S) batteries that is healable and highly conductive, overcoming longstanding challenges of traditional sulfur cathodes. The advance holds promise for bringing more energy dense and [...]
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results 03/06/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced [...]
Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 03/06/2024
Presentation will take place during the “Cancer Vaccines: Ready for Prime Time?” session on April 7, from 3:00 – 5:00pm PT at the San Diego Convention Center Presentation will take place during the “Cancer Vaccines: [...]
Araris Biotech AG to Present Data on Antibody-Drug Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 03/06/2024
AU ZH, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) — Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will be presenting one abstract and [...]
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 03/06/2024
LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an [...]
ALL SDBN NEWS | POST SDBN NEWS
